United States: A New Focus At FDA: Supply Chain And Import Challenges

Dr. Margaret A. Hamburg, the recently appointed Commissioner of the Food and Drug Administration ("FDA"), made an important statement during her first round of interviews since becoming Commissioner: "Under my new leadership, the industry can expect to see a more aggressive posture with respect to enforcement." This remark follows numerous signals by FDA over the past few weeks that the agency intends to toughen enforcement in several areas. These signals should be taken seriously. An "awakened" FDA will be funded with additional monies promised for FDA's budget and with funding proposed through legislation such as The Drug and Device Accountability Act of 2009 (S. 882). As a result, firms that manufacture, import, and distribute FDA-regulated products can anticipate being visited more often, and probably more critically, than in the past. This, in turn, will force a company to handle additional Inspectional Observations (FDA 483s), Warning Letters, and reinforcement actions.

Discussed below are two areas – supply chains and imports – in which FDA has begun to focus. Included in the discussion are suggestions firms may wish to consider in preparing for increased regulatory scrutiny.

Increased Focus on Supply Chain Management and Import-Related Inspections

Dr. Hamburg and Dr. Joshua Sharfstein, FDA's Principal Deputy Commissioner, signaled in a recent editorial in The New England Journal of Medicine that supply chain management is a priority at FDA. "Safety must be the shared responsibility of not only the producer but the country of origin, the importer, the importing country, and the final company in the supply chain." Supply chain management is not easy. As the number of entities involved in product development, manufacture, and distribution increases, the harder it is for a company to monitor the lifecycle of an FDA-regulated product.

A company's ability to manage successfully increased regulatory scrutiny will depend largely on the integrity of its supply chain management system. Companies should, therefore, review their supply chains now, before a regulatory agency identifies a problem. Not only does an effective supply chain management system reduce the likelihood of enforcement actions taken by a regulatory body (the system will reduce errors by protecting the supply chain), but it is also a signal to FDA that a company understands FDA's concerns about supply chain safety, and takes supply chain management seriously. The challenges presented by an increasingly complex global economy and a significant rise in imports has caused a paradigm shift in the way that FDA ensures that a product meets U.S. safety standards. Rather than continuing to use a traditional intervention, port-of-entry focused strategy (e.g., inspection and sampling) to protect the safety of imported products, FDA is transitioning to a risk-based, life-cycle approach that will hold all segments of a supply chain accountable. This approach will use both traditional and innovative mechanisms (e.g., third-party certifications and coordination with foreign regulatory agencies) to identify high-risk segments of a product life cycle, and to verify the safety of products at critical phases. Firms that acknowledge and adapt a risk-based supply chain management system will be in a more compliant posture when interacting with FDA.

Industry should act now. Firms can anticipate a doubling of the number of import field examinations in the next fiscal year (beginning Oct. 1, 2010) to an estimated 6,197, up from the FDA's projection of 2,870 for fiscal year 2009. For fiscal year 2009, the number of import samples collected, similarly, is projected to reach 586, up from 346 in fiscal year 2008. FDA also estimates it will double (from 1 percent to 2 percent) the number of import entries to be examined in fiscal year 2010.

FDA Supply Chain Safety and Import Initiatives

  • FDA Pilot Program:.. A company should evaluate and consider participating in FDA's new two-year Secure Supply Chain ("SCC") pilot program. The SCC program, one of several agency initiatives to enhance drug product safety, will be jointly administered by FDA's Office of Compliance in the Center for Drug Evaluation and Research ("CDER") and FDA's Office of Regulatory Affairs. The program is part of FDA's new risk-based approach to regulating drug imports, and is expected to increase the likelihood of expedited entry for specific finished drug products and APIs imported into the United States. Each applicant may designate up to five drugs for selection in the program. To qualify, applicants must meet the program's criteria, including a requirement that they maintain control over the drugs from the time of manufacture through entry into the United States. FDA is expected to announce the opening of the program in late 2009 or early 2010. The Federal Register announcement will include information about the application, the application process, and program criteria. Critics of the program (as described in the January 2009 Federal Register notice1) are concerned that it may not significantly reduce import clearance times because FDA, rather than adopting a system for random inspections, will conduct full electronic reviews of all participating products, with some entries receiving further FDA review or examination after the electronic review. Many also are concerned about FDA's ability to exclude a participant from the program if certain entities in the supply chain (e.g., applicant, foreign manufacturer, or consignee) receive a warning letter from FDA. This may occur regardless of whether the warning letter relates to a product that has been selected for inclusion in the SCC pilot program. These concerns and others that were submitted to FDA in January will likely impact the structure of the final program.
  • Good Importer Practices Guidance:.. Issued by several federal agencies, including FDA, in January 2009, the Draft Good Importer Practices Guidance2 ("Guidance") is a response to the Interagency Working Group on Import Safety's Action Plan for Import Safety: A Roadmap for Continual Improvement (Action Plan)3. The Guidance recommends that importers institute certain practices to identify and to minimize risks associated with imported products. Although directed at importers, the Guidance states that manufacturers also should "carefully consider" the Guidance. The safety concerns that gave rise to the need to issue the Guidance are evident when one considers U.S. food imports from China, which more than tripled in value between 2001 and 2008. FDA refusals of food shipments from China suggest recurring problems with filth, unsafe additives, labeling, and drug residues in fish and shellfish. Addressing these safety risks and others is extremely difficult, given the scope and array of complex issues. Now, rather than relying primarily on random import inspections and foreign governments, FDA is working to place the onus on companies to comply with good importer practices.

    The Good Importer Practices are broadly organized under four guiding principles:

    Establishing a Product Safety Management Program: Starting at the very top of an organization, an importer should have an organizational structure that fosters corporate responsibility for product safety. An effective product safety management program should have a defined management structure; have clearly defined employee roles and responsibilities; provide adequate training for employees; have documented policies, specifications, and procedures; have a process to analyze and evaluate risks in a product life cycle; encourage effective communication between interested parties; and have a formal quality assurance program.

    Knowing the Product and Applicable U.S. Requirements: To enhance their ability to identify and minimize potential hazards to customers, importers should have a good understanding of the products they import, the applicable regulatory requirements, and the compliance history of the products and firms involved in the products' design, production, and handling.

    Verifying Product and Company Compliance Throughout the Supply Chain and Product Life Cycle: Importers should ensure that the appropriate preventive controls have been implemented throughout the supply chain and life cycle of the product, and that the product and companies down the supply chain comply with all applicable U.S. requirements. An importer should take responsibility for evaluating problems that develop with its imported products prior to importation while under its control, or while under the control of domestic parties with which it conducts business, and for working closely with all parties in the supply chain when issues arise.

    Taking Corrective and Preventive Action: After detecting a problem, an importer should take corrective and preventive action to ensure similar problems do not recur, such as developing corrective action plans, identifying root causes of problems, and taking steps to remediate and prevent them from current and future shipments. Corrective action may involve terminating business relationships with non-compliant firms.
  • Qualified Trusted Importer Program ("QTIP"):.. A company may find it useful to obtain QTIP certification when it becomes available. FDA is considering endorsing QTIP as a voluntary certification program for certain importers. The QTIP program would certify the integrity of an importer's internal processes and controls with respect to product quality, supply chain security and trade compliance. As a certified QTIP importer, a company will be afforded interagency green lane status for imports and certain other benefits.

Increased Foreign and Domestic Inspections

FDA will increase its foreign and domestic inspections over the next few years. According to FDA's Center for Drug Evaluation and Research, Office of Compliance (CDER/OC), since 2001, the number of foreign manufactured drug products has more than doubled. Similarly, foreign manufacturing sites also have more than doubled. China and India have had the largest increases. During this time, FDA's inspection rate decreased by more than 41 percent. As the number of foreign manufacturers exporting FDA-regulated products to the United States continues to increase over the next few years, FDA's role in collaborating with foreign governments and sending FDA inspectors from its new foreign offices to non-U.S. sites is anticipated to increase. Domestic inspections also are expected to increase significantly, countering the previous trend.

In sum, companies may anticipate increased numbers of and more aggressive inspections. Deborah Autor, Director, CDER/OC, at the April 2009 Food and Drug Law Institute annual conference, stated that companies can expect "swift, aggressive action" by FDA after it identifies an inspection problem. Her remarks may foreshadow how little time a firm could have from inspection to an enforcement action. Company management should consider having response teams in place to handle these increased inspections and enforcement actions.

Subsequent installments will address what companies can do when confronted with an FDA inspection and enforcement action.


1 74 Fed. Reg. 2604 (January 15, 2009).

2 Guidance: http://www.fda.gov/RegulatoryInformation/Guidances/ucm125805.htm.

3 Action Plan: http://www.importsafety.gov/report/actionplan.pdf.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions